Arcturus Therapeutics Holdings (ARCT)
(Delayed Data from NSDQ)
$24.07 USD
+1.09 (4.74%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $24.02 -0.05 (-0.21%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ARCT 24.07 +1.09(4.74%)
Will ARCT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ARCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARCT
Gritstone bio Inc. (GRTS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for
ARCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie
Other News for ARCT
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
Cathie Wood-Led Ark Invest Dumps $4.3M Worth Of Nvidia Shares Amid Rebound — Swoops Into Buy Stock Of This Netflix Rival
Arcturus Therapeutics Enhances Board with Industry Expert Dr. Slaoui
Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT), BioNTech SE (BNTX) and Tempest Therapeutics (TPST)